NCT05924971 Aspirin for Postpartum Patients With Preeclampsia
| NCT ID | NCT05924971 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | MemorialCare Health System |
| Condition | Preeclampsia Postpartum |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2023-07-26 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 86 participants in total. It began in 2023-07-26 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.
Eligibility Criteria
Inclusion Criteria: * Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria. * Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic. Exclusion Criteria: * Patient age \<18 years old * Non-English or Non-Spanish speaking * Chronic hypertension diagnosed before 20 weeks' gestation * Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction) * Aspirin prescribed postpartum for any other medical condition * Bleeding disorder * Breastfeeding an infant with thrombocytopenia
Contact & Investigator
Megan C Oakes, MD MSCI
PRINCIPAL INVESTIGATOR
Miller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center
Frequently Asked Questions
Who can join the NCT05924971 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia Postpartum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05924971 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05924971 currently recruiting?
Yes, NCT05924971 is actively recruiting participants. Contact the research team at moakes2@memorialcare.org for enrollment information.
Where is the NCT05924971 trial being conducted?
This trial is being conducted at Long Beach, United States.
Who is sponsoring the NCT05924971 clinical trial?
NCT05924971 is sponsored by MemorialCare Health System. The principal investigator is Megan C Oakes, MD MSCI at Miller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center. The trial plans to enroll 86 participants.